Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10463028

Genetically modified non-human animals expressing human EPO

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457725

Methods of treating skin cancer by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10442856

Methods of treating obesity with anti-ANGPTL8 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10442864

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428135

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426146

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426848

Humanized FcγR mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428157

Dosing regimens for use with PCSK9 inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421804

Anti-Zika virus antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10406226

Method of manufacturing VEGF antagonist fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10406222

Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400025

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400036

Compositions and methods for increasing muscle mass and muscle strength by specifically an

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392430

Methods of making nucleic acid molecules encoding modified chimeric polypeptides with impr

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392439

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392432

Human antibodies to influenza hemagglutinin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10390522

Non-human animals having a humanized programmed cell death 1 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10377817

Human antibodies to GREM1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370449

Methods for treating skin infection by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10358487

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10358495

Anti-LAG3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10342876

Process for reducing subvisible particles in a pharmaceutical formulation

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10314904

Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted